Copyright
©The Author(s) 2017.
World J Gastroenterol. Jan 7, 2017; 23(1): 141-150
Published online Jan 7, 2017. doi: 10.3748/wjg.v23.i1.141
Published online Jan 7, 2017. doi: 10.3748/wjg.v23.i1.141
Figure 1 Study subjects’ flow diagram.
HbA1C: Glycated hemoglobin; NASH: Non-alcoholic steatohepatitis.
Figure 2 Changes in fibrosis scores in paired liver biopsies (n = 5 per arm) before and after 24 wk of treatment with placebo (A) or sitagliptin (B).
1In the placebo arm, 2 patients’ fibrosis scores increased from 2 to 3; 2In the sitagliptin arm, 2 patients’ fibrosis scores increased from 1 to 2.
- Citation: Joy TR, McKenzie CA, Tirona RG, Summers K, Seney S, Chakrabarti S, Malhotra N, Beaton MD. Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. World J Gastroenterol 2017; 23(1): 141-150
- URL: https://www.wjgnet.com/1007-9327/full/v23/i1/141.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i1.141